INS and type 1 diabetes mellitus: As mentioned above, another major focus of TaMADOR is to develop novel proteoform-specific assays that can specifically target islet prohormone proteoforms (eg, from proinsulin and proglucagon) as potential novel biomarkers of interest in T1D (15).